Personal information

Activities

Collapse all

Works (24)

Germline Genetic Testing in Breast Cancer: Utilization and Disparities in a Middle-Income Country

JCO Global Oncology
2025-03 | Journal article
DOI: 10.1200/GO-24-00337
Contributors: Alessandra Borba Anton de Souza; Carlos Barrios; Rafaela Gomes de Jesus; Tomas Reinert; Juliana Giacomazzi; Daniela D. Rosa; Eduardo Cronemberger; Gustavo Werutsky; José Bines; Geraldo Silva Queiroz et al.
Source: check_circle
Crossref

Oncological outcomes of breast-conserving surgery versus mastectomy following neoadjuvant chemotherapy in a contemporary multicenter cohort

Scientific Reports
2025-03-16 | Journal article
DOI: 10.1038/s41598-025-93491-7
Contributors: Francisco Pimentel Cavalcante; Felipe Pereira Zerwes; Ryane Alcantara; Eduardo Camargo Millen; Andre Mattar; Marcelo Antonini; Anne Dominique Nascimento Lima; José Bines; Fabrício Palermo Brenelli; Guilherme Garcia Novita et al.
Source: check_circle
Crossref

Dose dense versus 3 weekly AC during neoadjuvant chemoimmunotherapy for triple negative breast cancer

npj Breast Cancer
2024-08-14 | Journal article
DOI: 10.1038/s41523-024-00676-w
Contributors: Renata Colombo Bonadio; Isadora Martins de Sousa; Flávia Cavalcanti Balint; Ana Carolina Marin Comini; Monique Celeste Tavares; Fernanda Madasi; Jose Bines; Rafael Dal Ponte Ferreira; Daniela Dornelles Rosa; Candice Lima Santos et al.
Source: check_circle
Crossref

Data from Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine

2023-04-01 | Preprint
DOI: 10.1158/1078-0432.c.6532781
Contributors: Karama Asleh; Ana Lluch; Angela Goytain; Carlos Barrios; Xue Q. Wang; Laura Torrecillas; Dongxia Gao; Manuel Ruiz-Borrego; Samuel Leung; José Bines et al.
Source: check_circle
Crossref

Data from Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine

2023-04-01 | Preprint
DOI: 10.1158/1078-0432.c.6532781.v1
Contributors: Karama Asleh; Ana Lluch; Angela Goytain; Carlos Barrios; Xue Q. Wang; Laura Torrecillas; Dongxia Gao; Manuel Ruiz-Borrego; Samuel Leung; José Bines et al.
Source: check_circle
Crossref

Supplementary Data S1-S2 from Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine

2023-04-01 | Preprint
DOI: 10.1158/1078-0432.22488662
Contributors: Karama Asleh; Ana Lluch; Angela Goytain; Carlos Barrios; Xue Q. Wang; Laura Torrecillas; Dongxia Gao; Manuel Ruiz-Borrego; Samuel Leung; José Bines et al.
Source: check_circle
Crossref

Supplementary Data S1-S2 from Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine

2023-04-01 | Preprint
DOI: 10.1158/1078-0432.22488662.v1
Contributors: Karama Asleh; Ana Lluch; Angela Goytain; Carlos Barrios; Xue Q. Wang; Laura Torrecillas; Dongxia Gao; Manuel Ruiz-Borrego; Samuel Leung; José Bines et al.
Source: check_circle
Crossref

Supplementary Figure S1 from Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine

2023-04-01 | Preprint
DOI: 10.1158/1078-0432.22488659
Contributors: Karama Asleh; Ana Lluch; Angela Goytain; Carlos Barrios; Xue Q. Wang; Laura Torrecillas; Dongxia Gao; Manuel Ruiz-Borrego; Samuel Leung; José Bines et al.
Source: check_circle
Crossref

Supplementary Figure S1 from Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine

2023-04-01 | Preprint
DOI: 10.1158/1078-0432.22488659.v1
Contributors: Karama Asleh; Ana Lluch; Angela Goytain; Carlos Barrios; Xue Q. Wang; Laura Torrecillas; Dongxia Gao; Manuel Ruiz-Borrego; Samuel Leung; José Bines et al.
Source: check_circle
Crossref

Supplementary Figure S2 from Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine

2023-04-01 | Preprint
DOI: 10.1158/1078-0432.22488656
Contributors: Karama Asleh; Ana Lluch; Angela Goytain; Carlos Barrios; Xue Q. Wang; Laura Torrecillas; Dongxia Gao; Manuel Ruiz-Borrego; Samuel Leung; José Bines et al.
Source: check_circle
Crossref

Supplementary Figure S2 from Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine

2023-04-01 | Preprint
DOI: 10.1158/1078-0432.22488656.v1
Contributors: Karama Asleh; Ana Lluch; Angela Goytain; Carlos Barrios; Xue Q. Wang; Laura Torrecillas; Dongxia Gao; Manuel Ruiz-Borrego; Samuel Leung; José Bines et al.
Source: check_circle
Crossref

Supplementary Figure S3 from Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine

2023-04-01 | Preprint
DOI: 10.1158/1078-0432.22488653
Contributors: Karama Asleh; Ana Lluch; Angela Goytain; Carlos Barrios; Xue Q. Wang; Laura Torrecillas; Dongxia Gao; Manuel Ruiz-Borrego; Samuel Leung; José Bines et al.
Source: check_circle
Crossref

Supplementary Figure S3 from Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine

2023-04-01 | Preprint
DOI: 10.1158/1078-0432.22488653.v1
Contributors: Karama Asleh; Ana Lluch; Angela Goytain; Carlos Barrios; Xue Q. Wang; Laura Torrecillas; Dongxia Gao; Manuel Ruiz-Borrego; Samuel Leung; José Bines et al.
Source: check_circle
Crossref

Supplementary Figure S4 from Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine

2023-04-01 | Preprint
DOI: 10.1158/1078-0432.22488650
Contributors: Karama Asleh; Ana Lluch; Angela Goytain; Carlos Barrios; Xue Q. Wang; Laura Torrecillas; Dongxia Gao; Manuel Ruiz-Borrego; Samuel Leung; José Bines et al.
Source: check_circle
Crossref

Supplementary Figure S4 from Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine

2023-04-01 | Preprint
DOI: 10.1158/1078-0432.22488650.v1
Contributors: Karama Asleh; Ana Lluch; Angela Goytain; Carlos Barrios; Xue Q. Wang; Laura Torrecillas; Dongxia Gao; Manuel Ruiz-Borrego; Samuel Leung; José Bines et al.
Source: check_circle
Crossref

Supplementary Figure S5 from Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine

2023-04-01 | Preprint
DOI: 10.1158/1078-0432.22488647
Contributors: Karama Asleh; Ana Lluch; Angela Goytain; Carlos Barrios; Xue Q. Wang; Laura Torrecillas; Dongxia Gao; Manuel Ruiz-Borrego; Samuel Leung; José Bines et al.
Source: check_circle
Crossref

Supplementary Figure S5 from Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine

2023-04-01 | Preprint
DOI: 10.1158/1078-0432.22488647.v1
Contributors: Karama Asleh; Ana Lluch; Angela Goytain; Carlos Barrios; Xue Q. Wang; Laura Torrecillas; Dongxia Gao; Manuel Ruiz-Borrego; Samuel Leung; José Bines et al.
Source: check_circle
Crossref

Supplementary Tables S1-S10 from Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine

2023-04-01 | Preprint
DOI: 10.1158/1078-0432.22488644
Contributors: Karama Asleh; Ana Lluch; Angela Goytain; Carlos Barrios; Xue Q. Wang; Laura Torrecillas; Dongxia Gao; Manuel Ruiz-Borrego; Samuel Leung; José Bines et al.
Source: check_circle
Crossref

Supplementary Tables S1-S10 from Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine

2023-04-01 | Preprint
DOI: 10.1158/1078-0432.22488644.v1
Contributors: Karama Asleh; Ana Lluch; Angela Goytain; Carlos Barrios; Xue Q. Wang; Laura Torrecillas; Dongxia Gao; Manuel Ruiz-Borrego; Samuel Leung; José Bines et al.
Source: check_circle
Crossref

Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine

Clinical Cancer Research
2023-01-17 | Journal article
DOI: 10.1158/1078-0432.CCR-22-2191
Contributors: Karama Asleh; Ana Lluch; Angela Goytain; Carlos Barrios; Xue Q. Wang; Laura Torrecillas; Dongxia Gao; Manuel Ruiz-Borrego; Samuel Leung; José Bines et al.
Source: check_circle
Crossref

Challenge of Incorporating New Drugs for Breast Cancer in Brazil: A Proposed Framework for Improving Access to Innovative Therapies

JCO Global Oncology
2021-12 | Journal article
DOI: 10.1200/GO.20.00566
Contributors: Carlos Barrios; Ruffo Freitas-Junior; Sandro Martins; Jose Bines; Maria Del Pilar Estevez-Diz; Maira Caleffi
Source: check_circle
Crossref

Practical considerations for expediting breast cancer treatment in Brazil

The Lancet Regional Health - Americas
2021-10 | Journal article
DOI: 10.1016/j.lana.2021.100028
Contributors: Gustavo Bretas; Nelson Luiz Renna; José Bines
Source: check_circle
Crossref

Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer

British Journal of Cancer
2021-07-06 | Journal article
DOI: 10.1038/s41416-021-01323-y
Contributors: José Bines; Emma Clark; Claire Barton; Eleonora Restuccia; Marion Procter; Amir Sonnenblick; Debora Fumagalli; Damien Parlier; Amal Arahmani; José Baselga et al.
Source: check_circle
Crossref

Does the Sequence of Anthracycline and Taxane Matter? The NeoSAMBA Trial

The Oncologist
2020-09-23 | Journal article
DOI: 10.1634/theoncologist.2019-0805
Contributors: José Bines; Isabele A Small; Roberta Sarmento; Fabiola Kestelman; Silvania Silva; Fabiana Resende Rodrigues; Lilian Faroni; Aline Gonçalves; Erika Ebecken; Pedro Maroun et al.
Source: check_circle
Crossref
How many people are using ORCID?